Pasithea Therapeutics (NASDAQ:KTTA) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Pasithea Therapeutics (NASDAQ:KTTA) issued its quarterly earnings data on Friday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.01, FiscalAI reports.

Pasithea Therapeutics Trading Up 0.4%

Shares of KTTA stock traded up $0.00 during trading hours on Friday, hitting $0.52. 2,355,348 shares of the company were exchanged, compared to its average volume of 558,271. The business has a 50 day moving average of $0.48 and a two-hundred day moving average of $0.62. Pasithea Therapeutics has a 52 week low of $0.28 and a 52 week high of $2.06. The company has a market capitalization of $17.44 million, a PE ratio of -0.33 and a beta of 0.39.

Analysts Set New Price Targets

A number of research firms have issued reports on KTTA. Zacks Research cut Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients. The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business.